Inceptive designs RNA molecules out of reach of traditional approaches using a combination of large scale deep learning algorithms and highly scalable assays. Our rapidly growing team of over 35 pioneers consists of key minds from the most impactful deep learning research groups and some of the most renowned biology labs.

Inceptive’s capabilities are focused on the design of therapeutic mRNA molecules with increased protein expression and chemical stability, two properties highly relevant to most mRNA therapeutics and vaccines.

We are active and already partnering with a large pharmaceutical company and are now looking to expand our reach with additional partnerships in all areas that will benefit from these capabilities, ranging from mRNA vaccines to mRNA-delivered antibodies, protein replacement therapies, gene editing and more complex biologics, including manufacturing thereof.

We are also bringing additional resources to expand our capabilities and our team, including the build out of a new facility addition to our lab in Palo Alto, Silicon Valley. Vancouver, BC is a recognized world class biohub for its expertise in genetic medicines, lipid nanoparticles formulation and biologics and would be an excellent candidate to support Inceptive’s growth and establish the company as a leader in the space of mRNA therapeutics.